Gilead Sciences Inc (GILD) is a Healthcare · Drug Manufacturers - General company listed on NASDAQ. Price $151.07 (+0.12%), Market cap $160.99B, P/E ratio 17.64, 52-week low–high $105.93 ~ $155.80.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further,
Financial statements, price targets, institutional (13F) holdings and related news for Gilead Sciences Inc are updated in real time on BlackAll Trade.
7 recent posts · 7 bullish · 0 bearish · 0 neutral.
Gilead Sciences Inc trades at $151.07 (+0.12%). Real-time quotes and charts are available on BlackAll Trade.
Gilead Sciences Inc has a market cap of about $160.99B. Its P/E ratio is 17.64.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company